Stephens Inc. AR Has $9.62 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Stephens Inc. AR grew its holdings in Zoetis Inc. (NYSE:ZTS) by 22.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 59,025 shares of the company’s stock after purchasing an additional 10,681 shares during the period. Stephens Inc. AR’s holdings in Zoetis were worth $9,617,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the third quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC increased its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC lifted its stake in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley dropped their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $215.00.

Zoetis Stock Down 1.6 %

Shares of NYSE ZTS opened at $171.37 on Monday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company’s 50 day moving average price is $169.26 and its 200-day moving average price is $179.22. The company has a market capitalization of $77.32 billion, a P/E ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.